Medicine
Rheon Medical is revolutionizing the surgical treatment of glaucoma
TechTransfer
EPFL
EPFL spin-off Rheon Medical has developed the world’s first adjustable glaucoma drainage system, which has already been used successfully in over 250 patients in Europe. The company, based at EPFL Innovation Park, closed a CHF 5.6 million Series C funding round in December 2020 and just received the U.S. FDA’s Breakthrough Device Designation for its technology.
Computer algorithms are currently revolutionising biology
Research
ETH Zurich
Artificial intelligence can help predict the three-dimensional structure of proteins. Beat Christen describes how such algorithms should soon help to develop tailored artificial proteins.
Lung cancer: Hope for increasing immunotherapy efficacy
Research
EPFL
A “paradox and setback” forced EPFL scientists to dig deeper when seeking a means to boost the power of immunotherapy in lung cancer. Understanding the problem – and finding the solution – has led to a promising potential therapy for some patients.
Illuminating tissue formation
Research
ETH Zurich
Researchers at ETH Zurich have developed a molecule that fluoresces where new tissue is forming in the body. Alongside helping to detect tumours, the molecule could play a significant role in research of wound healing disorders.
Laser improves the time resolution of CryoEM
Research
EPFL
EPFL scientists have devised a new method that can speed up the real-time observation capabilities of cryo-electron microscopy.
New blood test measures immunity against SARS-CoV-2
Research
EPFL
The Lausanne University Hospital (CHUV) and EPFL teamed up to develop a new test that’s sensitive enough to measure the amount of SARS-CoV-2 neutralizing antibodies present in the bloodstream. The scientists’ discovery, published in the prestigious Science Translational Medicine, opens promising new avenues for tracking immunity acquired by infection or vaccination. With this test, experts can measure the level of protection against variants of the virus and monitor their prevalence over time.
Page 32 of 37